|
|
| Product Name: | S55746 | | Synonyms: | S55746;S55746(S055746,BCL201);S55746 (Synonyms: BLC201);S55746 (BLC201);N-(4-hydroxyphenyl)-3-[6-[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-1,3-benzodioxol-5-yl]-N-phenyl-5,6,7,8-tetrahydroindolizine-1-carboxamide;BLC201;1-Indolizinecarboxamide, 3-[6-[[(3S)-3,4-dihydro-3-(4-morpholinylmethyl)-2(1H)-isoquinolinyl]carbonyl]-1,3-benzodioxol-5-yl]-5,6,7,8-tetrahydro-N-(4-hydroxyphenyl)-N-phenyl-;inhibit,BCL-201,Inhibitor,Bcl-2 Family,S55746,S-55746,BCL 201,BCL201,S 55746 | | CAS: | 1448584-12-0 | | MF: | C43H42N4O6 | | MW: | 710.82 | | EINECS: | | | Product Categories: | | | Mol File: | 1448584-12-0.mol |  |
| | S55746 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO : 50 mg/mL (70.34 mM);Water : < 0.1 mg/mL (insoluble) | | form | Solid | | color | White to off-white |
| | S55746 Usage And Synthesis |
| Description | S55746 (Bcl201, Servier-1) is orally available and has been reported to effectively kill cancer cells that overexpress Bcl-2 using both in vitro and in vivo models. Currently, S55746 as a single agent is in phase-I trials in relapsed or refractory CLL patients. As a sensitizing agent, S55746 is currently being tested for a combination use with PI3Kδinhibitor for follicular lymphoma and mantle cell lymphoma. |
| | S55746 Preparation Products And Raw materials |
|